Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | October 26, 2023 | October 30, 2023 |
| IMMUNIC, INC.VTL · Entity 6306 | Director | May 23, 2017 | May 25, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date October 26, 2023 · Filed October 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,201 |
Reported balance
After 2023-10-26 transaction · row 1
1 source rowRow 1 · 2023-10-26 · Grant · Acquired 1,625 · Balance 24,201 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
After 2023-10-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-10-26 · Grant · Acquired 3,937 · Balance 3,937 F1: The option vests on the earlier of the one year anniversary of the grant date (10/26/23) or the date of Bio-Techne's 2024 annual meeting of shareholders. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.84 · Expires 2025-10-28 | Direct | 17,040 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 17,040 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-26 | Direct | 15,940 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 15,940 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2023-10-26 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,460 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/26/23) or the date of Bio-Techne's 2024 annual meeting of shareholders.
IMMUNIC, INC.
Report date May 23, 2017 · Filed May 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2027-05-22 | Direct | 45,022 |
Reported balance
After 2017-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-23 · Grant · Acquired 45,022 · Balance 45,022 F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2023 Filed Oct 30, 2023 20:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019852 · form4.xml · derivative · entry 10 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/23) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019852 · form4.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,201 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010911 · form4-10312022_021014.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/22) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010911 · form4-10312022_021014.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,644 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000400 · edgar.xml · derivative · entry 8 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000400 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,306 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $91.78 | $0.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · derivative · entry 7 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $87.39 | $0.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · derivative · entry 6 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 500 | $511.45 | $255,725.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 5 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,112 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 4,600 | $510.23 | $2,347,052.48 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 4 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,612 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.98 to $510.597, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,900 | $509.33 | $1,477,045.69 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 3 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,212 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $508.978 to $509.769, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,000 | $91.78 | $367,120.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,000 | $87.39 | $349,560.00 |
DisclosureSEC source: 0000914190-21-000372 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · derivative · entry 10 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · derivative · entry 9 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,535 | $304.59 | $772,135.65 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 8 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,112 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $304.59 to $304.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 975 | $304.14 | $296,536.50 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 7 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,647 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.47 to $304.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,195 | $302.31 | $361,260.45 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 6 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,622 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.00 to $302.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,801 | $301.78 | $543,505.78 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 5 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,817 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.00 to $301.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,771 | $299.96 | $531,229.16 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 4 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,618 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.70 to $300.42, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,723 | $299.06 | $515,280.38 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 3 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,389 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.49 to $299.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $66.90 | $334,500.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $70.35 | $351,750.00 |
DisclosureSEC source: 0001562180-20-006656 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006500 · primarydocument.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 21:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006500 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,112 Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000013 · edgar.xml · derivative · entry 10 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000013 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,721 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:09 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004309 · primarydocument.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:09 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004309 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,226 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003385 · primarydocument.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/18) or the date of Bio-Techne's 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003385 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,712 Read SEC document |
| May 23, 2017 Filed May 25, 2017 21:38 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 45,022 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-17-000052 · wf-form4_149574829041849.xml · derivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,022 Underlying: Common Stock · 45,022 shares Expires 2027-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000857 · edgar.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000857 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.